GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview.
Digital breast tomosythesis now makes up close to 50% of mammography systems in the U.S. "Tomo is going to replace just straight digital mammography simply because of the benefit of fewer recalls," explained Debra L. Monticciolo, MD.
Debra L. Monticciolo, MD, past president of both the Society of Breast Imaging and the American College of Radiology, explains the advantages and disadvantages of current breast screening technology.
"A significant part of burnout stems from the overwhelming administrative burden," explains Elizabeth Ann Ignacio, MD, FSIR, FACR, chair of the SIR Small and Rural Practices Committee.
Marielle Scherrer-Crosbie, MD, told Cardiovascular Business that the current lack of reimbursement for strain echocardiography has been a challenge for care teams.
ASNC President Lawrence Phillips, MD, wants to see nuclear cardiologists modernize their labs and embrace new strategies for the evaluation of amyloidosis, sarcoidosis and inflammation.
Lyle McMillin, with radiology IT vendor Hyland, explains trends he sees in the market and a definite shift toward cloud and enterprise imaging to address challenges in the market.
GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview.
Ultrafast MCE could go on to become a go-to treatment option for obstructive coronary artery disease, according to the authors of a new first-in-human clinical study.